Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?

被引:49
作者
Watkins, Richard R. [1 ,2 ]
Deresinski, Stan [3 ]
机构
[1] Cleveland Clin Akron Gen, Div Infect Dis, Akron, OH 44302 USA
[2] Northeast Ohio Med Univ, Dept Med, Rootstown, OH USA
[3] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
关键词
Sepsis; nephrotoxicity; vancomycin; piperacillin/tazobactam; ACUTE KIDNEY INJURY; INFECTIOUS-DISEASES SOCIETY; CRITICALLY-ILL PATIENTS; RISK-FACTORS; CONCOMITANT VANCOMYCIN; HOSPITALIZED-PATIENTS; RENAL TOXICITY; TAZOBACTAM; CEFEPIME; GUIDELINES;
D O I
10.1093/cid/cix675
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Early administration of appropriate empiric antibiotics is essential for achieving the best possible outcomes in sepsis. Yet the choice of antibiotic therapy has become more challenging due to recent reports of nephrotoxicity with the combination of vancomycin and piperacillin/tazobactam, the "workhorse" regimen at many institutions. In this article we assess the evidence for nephrotoxicity and its possible mechanisms, provide recommendations for risk mitigation, address the advantages and disadvantages of alternative antibiotic choices, and suggest areas for future research.
引用
收藏
页码:2137 / 2143
页数:7
相关论文
共 50 条
  • [31] Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem
    Mefford, Breanne
    Wallace, Katie L.
    Donaldson, J. Chris
    Turpin, Brittany D. Bissell
    Sen, Parijat
    Schadler, Aric D.
    Liu, Lucas J.
    Bastin, Melissa L. Thompson
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (05)
  • [32] Are Patients Receiving the Combination of Vancomycin and Piperacillin-Tazobactam at Higher Risk for Acute Renal Injury?
    Long, Brit
    April, Michael D.
    ANNALS OF EMERGENCY MEDICINE, 2018, 72 (04) : 467 - 469
  • [33] Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model
    Pais, Gwendolyn M.
    Liu, Jiajun
    Avedissian, Sean N.
    Hiner, Danielle
    Xanthos, Theodoros
    Chalkias, Athanasios
    d'Aloja, Ernesto
    Locci, Emanuela
    Gilchrist, Annette
    Prozialeck, Walter C.
    Rhodes, Nathaniel J.
    Lodise, Thomas P.
    Fitzgerald, Julie C.
    Downes, Kevin J.
    Zuppa, Athena F.
    Scheetz, Marc H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (05) : 1228 - 1236
  • [34] Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime
    Quach, Henry T.
    Esbenshade, Adam J.
    Zhao, Zhiguo
    Banerjee, Ritu
    PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
  • [35] Nut Cracked? Does the ACORN Trial End the Debate Surrounding Vancomycin and Piperacillin-Tazobactam Combination Therapy and Increased Risk for Acute Kidney Injury?
    Pogue, Jason M.
    Aitken, Samuel L.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (01):
  • [36] Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury
    Abdullah Tarık Aslan
    Tural Pashayev
    Osman Dağ
    Murat Akova
    European Journal of Clinical Microbiology & Infectious Diseases, 2021, 40 : 1953 - 1961
  • [37] Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury
    Aslan, Abdullah Tarik
    Pashayev, Tural
    Dag, Osman
    Akova, Murat
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021, 40 (09) : 1953 - 1961
  • [38] Pharmacists' perceptions and practice changes resulting from emergence of the vancomycin-piperacillin/tazobactam nephrotoxicity phenomenon
    Hammond, Drayton A.
    Trivedi, Abhaya P.
    Esmero, Veronica M.
    Hamadeh, Leena
    Heikkinen, Benjamin
    Tan, Carrie
    Hanson, Amy
    Rech, Megan A.
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2020, 3 (02): : 410 - 416
  • [39] A Comparison of Nephrotoxicity in Non-Intensive Care Unit Medical-Surgical Patients Receiving Vancomycin Alone Versus Vancomycin With Piperacillin-Tazobactam
    Eberle, Hannah
    Rogers, Maegan
    Lee, Marilyn
    Hill, David
    Cross, Sara
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2018, 26 (01) : 23 - 26
  • [40] Exploring the Role of Piperacillin and Tazobactam in Combination with Vancomycin against Methicillin-ResistantStaphylococcus aureus
    Dilworth, Thomas J.
    Sanchez, Daniel
    Anderson, Beverly
    DeAngelis, Haedi
    Mercier, Renee-Claude
    CHEMOTHERAPY, 2020, 64 (5-6) : 233 - 237